DOP2007000122A - Forma farmacologica peroral para anticoncepcion - Google Patents

Forma farmacologica peroral para anticoncepcion

Info

Publication number
DOP2007000122A
DOP2007000122A DO2007000122A DO2007000122A DOP2007000122A DO P2007000122 A DOP2007000122 A DO P2007000122A DO 2007000122 A DO2007000122 A DO 2007000122A DO 2007000122 A DO2007000122 A DO 2007000122A DO P2007000122 A DOP2007000122 A DO P2007000122A
Authority
DO
Dominican Republic
Prior art keywords
peroral
contraception
dienogest
less
daily dosage
Prior art date
Application number
DO2007000122A
Other languages
English (en)
Inventor
Sabine Fricke
Alexander Buske
Hagen Gerecke
Herbert Wiesinger
Ralf Ladwig
Original Assignee
Bayer Schering Fharma Aktiegesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Fharma Aktiegesellschaft filed Critical Bayer Schering Fharma Aktiegesellschaft
Publication of DOP2007000122A publication Critical patent/DOP2007000122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

Una forma farmacológica peroral para la anticoncepción contiene como un componente de principio activo 17a-cianometil-17-f3-hidroxiestra-4,9dien-3-ona (dienogest) en una dosificación diaria de igual o menor que 2,0 mg y como otro componente de principio activo 17a-etinilestradiol (etinilestradiol) en una dosificación diaria menor que 0,03 mg junto con uno o varios vehículos de aceptación farmacéutica. El principio activo dienogest está contenido en forma cristalina con un tamaño de partícula promedio de 25 a 70 pm. El principio activo etinilestradiol se incorpora en forma micronizada o como solución etanólica durante la granulación.
DO2007000122A 2006-08-10 2007-08-09 Forma farmacologica peroral para anticoncepcion DOP2007000122A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06016694A EP1886694B1 (de) 2006-08-10 2006-08-10 Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption

Publications (1)

Publication Number Publication Date
DOP2007000122A true DOP2007000122A (es) 2008-02-15

Family

ID=37561777

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2007000122A DOP2007000122A (es) 2006-08-10 2007-08-09 Forma farmacologica peroral para anticoncepcion

Country Status (18)

Country Link
EP (1) EP1886694B1 (es)
AR (1) AR062323A1 (es)
AT (1) ATE432714T1 (es)
CL (1) CL2007002323A1 (es)
CY (1) CY1110348T1 (es)
DE (1) DE502006003892D1 (es)
DK (1) DK1886694T3 (es)
DO (1) DOP2007000122A (es)
ES (1) ES2327665T3 (es)
HR (1) HRP20090438T1 (es)
NO (1) NO20091057L (es)
PE (1) PE20080541A1 (es)
PL (1) PL1886694T3 (es)
PT (1) PT1886694E (es)
SI (1) SI1886694T1 (es)
TW (1) TW200817012A (es)
UY (1) UY30530A1 (es)
WO (1) WO2008017331A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
CN115487198B (zh) * 2022-09-20 2024-01-02 华中药业股份有限公司 一种快溶出度的左炔诺孕酮制剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
ES2327665T3 (es) 2009-11-02
NO20091057L (no) 2009-03-09
ATE432714T1 (de) 2009-06-15
PL1886694T3 (pl) 2009-11-30
DE502006003892D1 (de) 2009-07-16
DK1886694T3 (da) 2009-09-28
TW200817012A (en) 2008-04-16
EP1886694B1 (de) 2009-06-03
PT1886694E (pt) 2009-08-17
UY30530A1 (es) 2008-03-31
AR062323A1 (es) 2008-10-29
WO2008017331A3 (de) 2009-01-08
HRP20090438T1 (en) 2009-09-30
PE20080541A1 (es) 2008-07-10
SI1886694T1 (sl) 2009-10-31
CL2007002323A1 (es) 2008-02-15
WO2008017331A2 (de) 2008-02-14
EP1886694A1 (de) 2008-02-13
CY1110348T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
RS53876B1 (en) PARENTERAL PHARMACEUTICAL FORM, WHICH RELEASES AROMATASE AND GESTAGEN BLOCKERS, FOR THE TREATMENT OF ENDOMETRIOSIS
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
JP2010539153A5 (es)
DOP2007000122A (es) Forma farmacologica peroral para anticoncepcion
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
DOP2006000035A (es) Preparación farmaceútica para la anticoncepción oral
AR056694A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
CR10912A (es) Preparacion framaceutica para reducir la endometriosis
CR9240A (es) Forma farmacologica peroral solida para la anticoncepcion
UY29378A1 (es) Preparación farmaceutica para la anticoncepción oral
TH80558B (th) รูปแบบยาทางช่องปากชนิดแข็งสำหรับการคุมกำเนิด
PE20091020A1 (es) Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa
CL2012000499A1 (es) Forma de dosificación farmacéutica sólida oral de liberación extendida que comprende una formulación matricial de liberación extendida que comprende 5 a 500 mg de clorhidrato de oxicodona y al menos 80 % (p/p) de oxido de polietileno (pm 1.000.000); y su uso para tratar el dolor (div. sol. n° 200702485).
TH80558A (th) รูปแบบยาทางช่องปากชนิดแข็งสำหรับการคุมกำเนิด
NZ737002A (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
PE20091695A1 (es) COMBINACION FARMACEUTICA DE DROSPIRENONA Y 17ß-ESTRADIOL
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas